	US 12,030,954 B2
	Antibody binding to AXL protein and application thereof
Ming Lv, Zhejiang (CN); Xiaoran Ding, Zhejiang (CN); Shiwei Miao, Zhejiang (CN); Bin Tan, Zhejiang (CN); and Xuegong Wang, Zhejiang (CN)
Assigned to HANGZHOU SUMGEN BIOTECH CO., LTD., Zhejiang (CN); and SUMGEN MAB (BEIJING) BIOTECH CO., LTD., Beijing (CN)
Appl. No. 17/059,019
Filed by HANGZHOU SUMGEN BIOTECH CO., LTD., Zhejiang (CN); and SUMGEN MAB (BEIJING) BIOTECH CO., LTD., Beijing (CN)
PCT Filed May 28, 2019, PCT No. PCT/CN2019/088794 § 371(c)(1), (2) Date Nov. 25, 2020, PCT Pub. No. WO2019/228345, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. 201810528095.2 (CN), filed on May 29, 2018.
Prior Publication US 2021/0230295 A1, Jul. 29, 2021
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/40 (2006.01)

CPC C07K 16/30 (2013.01) [A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01)]

14 Claims

1. An antibody or antigen-binding fragment thereof, which is capable of binding to an AXL protein, comprising a light chain variable region and a heavy chain variable region,

said light chain variable region comprises LCDR1, LCDR2 and LCDR3,

said LCDR1 comprises the amino acid sequence of SEQ ID NO:4;

said LCDR2 comprises the amino acid sequence of SEQ ID NO:5;

said LCDR3 comprises the amino acid sequence of SEQ ID NO:6;

said heavy chain variable region comprises HCDR1, HCDR2 and HCDR3,

said HCDR1 comprises the amino acid sequence of SEQ ID NO:7;

said HCDR2 comprises the amino acid sequence of SEQ ID NO:8; and

said HCDR3 comprises the amino acid sequence of SEQ ID NO:9.